U.S. markets open in 2 hours 55 minutes
  • S&P Futures

    4,453.75
    -21.00 (-0.47%)
     
  • Dow Futures

    34,549.00
    -67.00 (-0.19%)
     
  • Nasdaq Futures

    14,713.00
    -128.00 (-0.86%)
     
  • Russell 2000 Futures

    2,018.90
    -2.30 (-0.11%)
     
  • Crude Oil

    83.95
    -1.60 (-1.87%)
     
  • Gold

    1,834.60
    -8.00 (-0.43%)
     
  • Silver

    24.44
    -0.28 (-1.12%)
     
  • EUR/USD

    1.1333
    +0.0015 (+0.14%)
     
  • 10-Yr Bond

    1.8330
    0.0000 (0.00%)
     
  • Vix

    26.66
    +2.81 (+11.78%)
     
  • GBP/USD

    1.3555
    -0.0045 (-0.33%)
     
  • USD/JPY

    113.8340
    -0.2660 (-0.23%)
     
  • BTC-USD

    38,828.93
    -3,275.94 (-7.78%)
     
  • CMC Crypto 200

    917.56
    -77.70 (-7.81%)
     
  • FTSE 100

    7,521.41
    -63.60 (-0.84%)
     
  • Nikkei 225

    27,522.26
    -250.67 (-0.90%)
     

Why NRx Pharmaceuticals Stock Soared Today

·1 min read
Why NRx Pharmaceuticals Stock Soared Today
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • GILD

Shares of NRx Pharmaceuticals (NASDAQ: NRXP) surged on Monday after the healthcare company released promising clinical trial data for its investigational COVID-19 treatment, aviptadil. An analysis conducted by respected statistician Dr. David Schoenfeld found that patients treated with aviptadil had a significantly higher probability of recovering from critical COVID-19 and respiratory failure than those who received existing therapies. Among those who previously received Gilead Sciences' (NASDAQ: GILD) remdesivir, patients treated with aviptadil were 2.5 times more likely to be alive and free of respiratory failure at 60 days than those who received a placebo.